CVD Risk Reduction and Lipid Management - 51

Meta-Analysis: Effects of Nicotinic Acid
Major Coronary Events
Study ARBITER-6-HALTS Guyton JR et al AFREGS ARBITER-2 HATS UCSF_SCOR STOCKHOLM CLAS CDP Treatment n/N 2/187 1/676 0/71 2/87 1/38 0/48 72/279 1/94 287/1119 9/176 1/272 1/72 2/80 5/38 1/49 100/276 5/94 839/2789 Control n/N Peto OR 95% Cl Peto OR 95% Cl 0.25 (0.08, 0.84) 0.35 (0.02, 7.56) 0.14 (0.00, 6.92) 0.92 (0.13, 6.65) 0.24 (0.05, 1.26) 0.14 (0.00, 6.96) 0.61 (0.43, 0.88) 0.25 (0.05, 1.29) 0.81 (0.69, 0.94) 0.75 (0.65, 0.86) 0.53 (0.38, 0.73) 0.1 0.2 0.5 1 2 5 10
Log scale

Total Test for heterogeneity: P = 0.24, I2 = 23.0% Test for overall effect: P < 0.0001 Subtotal excluding CDP

Many of these trials were tests of drug combinations that included niacin
Bruckert E et al. Atherosclerosis. 2010;210:353-361.



CVD Risk Reduction and Lipid Management

Table of Contents for the Digital Edition of CVD Risk Reduction and Lipid Management

CVD Risk Reduction and Lipid Management - 3
CVD Risk Reduction and Lipid Management - 5
CVD Risk Reduction and Lipid Management - 6
CVD Risk Reduction and Lipid Management - 7
CVD Risk Reduction and Lipid Management - 8
CVD Risk Reduction and Lipid Management - 9
CVD Risk Reduction and Lipid Management - 10
CVD Risk Reduction and Lipid Management - 11
CVD Risk Reduction and Lipid Management - 12
CVD Risk Reduction and Lipid Management - 13
CVD Risk Reduction and Lipid Management - 14
CVD Risk Reduction and Lipid Management - 15
CVD Risk Reduction and Lipid Management - 16
CVD Risk Reduction and Lipid Management - 17
CVD Risk Reduction and Lipid Management - 18
CVD Risk Reduction and Lipid Management - 19
CVD Risk Reduction and Lipid Management - 20
CVD Risk Reduction and Lipid Management - 21
CVD Risk Reduction and Lipid Management - 22
CVD Risk Reduction and Lipid Management - 23
CVD Risk Reduction and Lipid Management - 24
CVD Risk Reduction and Lipid Management - 25
CVD Risk Reduction and Lipid Management - 26
CVD Risk Reduction and Lipid Management - 27
CVD Risk Reduction and Lipid Management - 28
CVD Risk Reduction and Lipid Management - 29
CVD Risk Reduction and Lipid Management - 30
CVD Risk Reduction and Lipid Management - 31
CVD Risk Reduction and Lipid Management - 32
CVD Risk Reduction and Lipid Management - 33
CVD Risk Reduction and Lipid Management - 34
CVD Risk Reduction and Lipid Management - 35
CVD Risk Reduction and Lipid Management - 36
CVD Risk Reduction and Lipid Management - 37
CVD Risk Reduction and Lipid Management - 38
CVD Risk Reduction and Lipid Management - 39
CVD Risk Reduction and Lipid Management - 40
CVD Risk Reduction and Lipid Management - 41
CVD Risk Reduction and Lipid Management - 42
CVD Risk Reduction and Lipid Management - 43
CVD Risk Reduction and Lipid Management - 44
CVD Risk Reduction and Lipid Management - 45
CVD Risk Reduction and Lipid Management - 46
CVD Risk Reduction and Lipid Management - 47
CVD Risk Reduction and Lipid Management - 48
CVD Risk Reduction and Lipid Management - 49
CVD Risk Reduction and Lipid Management - 50
CVD Risk Reduction and Lipid Management - 51
CVD Risk Reduction and Lipid Management - 52
CVD Risk Reduction and Lipid Management - 53
CVD Risk Reduction and Lipid Management - 54
CVD Risk Reduction and Lipid Management - 55
CVD Risk Reduction and Lipid Management - 56
CVD Risk Reduction and Lipid Management - 57
CVD Risk Reduction and Lipid Management - 58
CVD Risk Reduction and Lipid Management - 59
CVD Risk Reduction and Lipid Management - 60
CVD Risk Reduction and Lipid Management - 61
CVD Risk Reduction and Lipid Management - 62
CVD Risk Reduction and Lipid Management - 63
CVD Risk Reduction and Lipid Management - 64
CVD Risk Reduction and Lipid Management - 65
CVD Risk Reduction and Lipid Management - 66
https://www.nxtbookmedia.com